vendredi 14 décembre 2018

Onco Actu du 14 décembre 2018

2. Etiologie

Breast Cancer Risk May Rise After Childbirth, but Is Still Low [NY Times]

2.4 Etiologie - Portables, ondes e-m

New Australian study finds no link between mobile phone use and brain cancers [Australian Government]

3.4 Chimioprévention

Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows [NCI]

3.6 Prévention - Activité physique

Exercise Significantly Cuts the Risk of Death from Cancer [Roswell Park]

4.1 Dép., diag. & prono. - Prostate

Specialist MRI scans recommended to help diagnose prostate cancer on NHS [Cancer Research UK]

4.12 Biopsies liquides

Liverpool scientists awarded £2.17 million by Cancer Research UK to spot pancreatic cancer early [Cancer Research UK]

4.2 Dép., diag. & prono. - Génome

Why Every Pancreatic Cancer Patient Should Consider Genetic Testing [Michigan Health]

4.9 Dép., diag. & prono. - Sein

Breast Cancer Subtype-Specific Polygenic Risk Scores Identified [Genome Web]

Internal PHE investigation into the national breast screening incident of 2018 [Public Health England]

Jeremy Hunt wrong in breast cancer screening statement, inquiry says [The Guardian]

5.12.8 Immunothérapies - Economie

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS [Cancer Research UK]

5.2.3 Pharma - économie

A new analysis spotlights the top 20 drugs in the late-stage pipeline [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

FDA hails 2018 as bumper year for drug development successes [FierceBiotech]

5.4 Traitements - Economie

Cure ‘futures’ offer a way to pay for million-dollar medicines [STAT]

5.6.7 ESMO - Immunothérapies

AstraZeneca mines for positives in Imfinzi's failed Mystic lung cancer trial [FiercePharma]

Can Bristol-Myers' latest Opdivo results preserve its small-cell lung cancer nod? [FiercePharma]

First Line Immunotherapy Combination Fails to Improve Overall Survival in Lung Cancer [ESMO Press Release]

Second-Line Nivolumab Is Not Superior to Chemotherapy in SCLC [ESMO]

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer [Boehringer Ingelheim]

Esmo-IO – Astrazeneca plays its tumour mutation burden card [Vantage]


Research Highlights from the San Antonio Breast Cancer Symposium 2018 [Cancer Research Catalyst]

6.10.1 Politiques (USA)

NIH considers restrictions to counter foreign influence in research [Nature]

6.7.1 IA/bioinformatique

Artificial intelligence and the future of medicine [WUSTL]

6.8 Communication

Key opinion leaders’ guide to spinning a disappointing clinical trial result [BMJ Christmas 2018]

Plan to ban ads suggesting medical treatment for cancer is unnecessary [Irish Times]